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Abstract
Infectious complications are common and sometimes life threatening in patients with immune thrombocytopenia (ITP), mainly
due to the immune-suppressive therapy. Recent evidence suggests a potential role of platelets in the inflammation process. In this
clinical study, we further investigated the role of thrombocytopenia on infections in patients with primary ITP.We retrospectively
evaluated data from the recently published large randomized clinical trial of a cohort of 195 patients with primary ITP, who were
randomized for prednisone or high-dose dexamethasone. From 158 patients (81%), data on platelet count and infections within
the first month of treatment were collected. In this period, 24% of the ITP patients had an infection. Patients with infection had
significant lower platelet counts during the first month of treatment leading to a significant lower therapy response at 1 month and
a significant longer hospital stay (14.0 versus 9.8 days). Additionally, Cox regression analysis showed that an increase in platelet
count of 20 × 109/L led to a reduction of 52% in infections in the next week, showing low platelet count is a significant risk factor
for infection. Platelet transfusion led to an increase in platelet count in ITP patients without infection, but not in patients with
infection. In conclusion, infections are common in patients with primary ITP leading to significant worse response rates and a
longer hospital stay. Interestingly, low platelet count was independently correlated with an increased risk of infection.
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Introduction
Immune thrombocytopenia (ITP) is an autoimmune disease
characterized by autoantibody-induced platelet destruction
and decreased platelet production often resulting in mild
bleeding symptoms (e.g., petechiae) to severe bleeding man-
ifestations (e.g., intracranial hemorrhage) [1, 2]. Diagnosis is
made by exclusion of other causes of the thrombocytopenia,
e.g., infections. In patients with chronic ITP, infections are
common, withmajor morbidity andmortality [3, 4]. It is main-
ly considered that treatment of ITP increases the risk of infec-
tions (e.g., corticosteroids, and other immunosuppressive
agents). However, recently, it is shown that infection is not
only related to the immunosuppressive treatment in chronic
ITP but also to the etiology of the disease itself [5]. New
studies show that platelets play a role in the immune response,
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but knowledge of the clinical importance is still limited, espe-
cially in primary ITP patients [6–10]. To further elucidate the
role of platelets in risk of infection, we analyzed data of a
cohort of primary ITP patients from the recently published
prospective randomized multicenter clinical trial of Wei et
al. [11].
Materials and methods
Study design
In the prospective, multicenter, randomized, controlled,
open-label clinical trial of Wei et al., newly diagnosed
ITP patients were randomized for high-dose dexametha-
sone (HD-DXM) or prednisone (PDN) for first-line man-
agement [11]. Patients in the HD-DXM arm received
DXM orally at 40 mg for 4 consecutive days and then
stopped. If platelet count remained low (< 30 × 109/L) or
there were bleeding symptoms by day 10, an additional 4-
day course of DXM (40 mg daily) was given. Patients in
the PDN arm received PDN orally at 1.0 mg/kg body
weight daily for four consecutive weeks. No dose adjust-
ments were made so all patients in both groups received
the intended and same dose of immunosuppressive thera-
py. Platelet count was measured according routine local
laboratory practice at days 0, 7, 14, 21, and 28 after ran-
domization. The study was conducted in collaboration
among nine separate investigation sites in China. Data
were collected from each participating site and sent to
the principal investigation site at Qilu Hospital,
Shandong University, for analysis. The study protocol
was approved by the ethics committee on medical re-
search of each participating site. All patients provided
written informed consent in accordance with the
Declaration of Helsinki before enrollment.
Patients
Inclusion criteria were patients with primary ITP, without pri-
or treatment. Exclusion criteria were seropositive detection of
HIV, hepatitis B virus or hepatitis C virus, pregnancy or lac-
tation, active infection, hypertension, diabetes, cardiovascular
diseases, liver and kidney function impairment, psychosis and
osteoporosis, and life-threatening bleeding (e.g., massive
hemorrhage with severe anemia, central nervous system
bleeding). No prophylactic antibiotics were given during first
month of treatment with steroids.
Infections
Primary outcome in the study of Wei et al. was initial
response and sustained response based on platelet counts.
As adverse event, three infections were measured in this
study [11]. Definition of infection was different than ours;
they measured only severe infections caused by immuno-
suppressive therapy (e.g., one patient terminated immuno-
suppressive therapy due to infection). As our focus is on
the role of platelets on infection, we used a different,
broader, definition for infections. In our study, infections
with a grade 2 or more were scored according to the
Common Terminology Criteria for Adverse Events
(CTCAE) grading scale (version 4.03: June 14, 2010),
including viral, bacterial, and fungal episodes.
Statistical analysis
Baseline characteristics were summarized using descrip-
tive statistics. Continuous variables were summarized as
median or mean ± standard deviation or standard error of
the mean, and categorical variables were summarized
using frequencies and percentages. Differences between
the groups were analyzed with t tests or with nonparamet-
ric Mann-Whitney test when not normally distributed. To
evaluate the relationship between platelet count and infec-
tions, we used Spearman correlation coefficient. To adjust
for time of infection, we used Cox regression analysis
with platelet count as time-varying covariate; platelet
counts were categorized into groups of 20 × 109/L, and
the last platelet count before the time of occurrence of
infection was used for analysis, e.g., when infection oc-
curred at 10 days after randomization, the platelet count
from day 7 was used. Risk of infection was presented as
hazard ratio. All p values are two-sided, and p values <
0.05 were considered statistically significant.
Results
Baseline characteristics
Between January 2011 and May 2014, 261 patients were
screened for eligibility and 195 patients with primary ITP
were randomized in the study of Wei et al. [11]. From this
patient population, data on platelet count and infection of
158 patients could be collected retrospectively. In the first
month after randomization, infection occurred in 24% of the
patients: 120 patients had no infection and 38 patients had a
viral or bacterial infection. Baseline characteristics of both
patient groups are summarized in Table 1. There were no
differences in age, sex, antibodies, and type of treatment.
Except for leucocyte count at t = 0, no differences were found
for blood values between the two study groups. Usage of type
of steroids was similar for both groups.
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Infection leads to lower response rates and prolonged
hospital stay
Mean platelet counts during the first month after randomiza-
tion are shown for patients with and without infection in
Fig. 1. Platelet count at t = 0 was the same for both groups:
13.8 × 109/L for the patients without infection and 11.8 × 109/
L for the patients with infection (p > 0.05) (Table 1). However,
during the first month, patients with infection had significant
lower platelet counts than patients without infections at 1, 2,
and 4 weeks (p < 0.01). Only, the lower platelet count at
3 weeks for the patients with infection was not statistically
significant. According to the response criteria of Rodeghiero
et al., a significant lower response at 1 month is found for
patients with infection as shown in Fig. 2 (p < 0.05) [2].
Additionally, infection is also associated with a significant
longer hospital stay, e.g., 9.8 ± 5.2 days for patients without
infection and 14.0 ± 8.7 days for patients with infection (Table
*
* *
Fig. 1 Infection leads to lower
platelet counts in patients with
primary ITP. Mean platelet counts
(± s.e.m.) during the first month
after therapy in patients with
primary ITP with and without
infection. *p < 0.01
Table 1 Patient demographics
and baseline characteristics Characteristic Overall
(N = 158)
No Infections
(N = 120)
Infections
(N = 38)
Age (year) 42 ± 16 42 ± 16 42 ± 16
Sex (m/f) 51/107 37/83 14/24
Hemoglobin value (mg/dL) at t = 0 123.2 ± 28.6 122.1 ± 30.8 126.8 ± 20.1
Leucocyte count (× 109/L) at t = 0 7.7 ± 3.4 7.2 ± 3.2 9.1 ± 3.6*
Platelet count (× 109/L) at t = 0 13.4 ± 12.2 13.8 ± 12.8 11.8 ± 10.4
Hemoglobin value (mg/dL) at t = 1 month 125.5 ± 32.2 124.0 ± 23.9 130.4 ± 50.3
Leucocyte count (× 109/L) at t = 1 month 11.0 ± 7.9 11.2 ± 7.8 10.5 ± 8.2
Platelet count (× 109/L) at t = 1 month 87.7 ± 78.7 107.4 ± 79.7 25.4 ± 24.3*
Bleeding score 3.9 ± 3.4 3.8 ± 3.5 4.1 ± 3,2
Duration hospital stay (days) 10.9 ± 6.5 9.8 ± 5.2 14.0 ± 8.7*
Treatment (dexamethasone/prednisone) 118/40 87/33 31/7
Antibodies
None 46 35 11
GPIb-IX 13 11 2
GPIIbIIIa 15 7 8
Both 18 16 2
Unknown 66 51 15
Type of infection
Viral 11
Bacterial 27
Time of infection (day) 5.7 ± 5.1
Platelet transfusion
Number of patients transfused 91 (57.6%) 62 (51.7%) 29 (76.3%)
Total amount of units 150 91 59
Median amount of units 1 1 1
Mean 1.0 0.8 1.6*
Mean values for age, platelet count, leucocyte count, hemoglobin values, bleeding score, hospital stay, and time of
infection ± standard deviations are shown. Bleeding score was calculated by adding the points relevant to various
clinical bleeding signs as described by Wei et al. [11]
*p < 0.01
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1) (p < 0.01). In both groups, none of the patients had a throm-
botic event, e.g., deep venous thrombosis or pulmonary em-
bolism, during the first month of treatment. At 1 month, no
differences were found between patients with and without
infection in mean hemoglobin value (124.0 vs 130.4 g/L,
p > 0.05) and leucocyte count (11.2 × 109 vs 10.5 × 109/L,
p > 0.05).
Low platelet count is correlated with increased risk
of infection
As shown in Fig. 1, lower platelet counts led to more infec-
tions. Platelet count at 1 month was significantly correlated
with infection with a Spearman correlation coefficient of −
0.517 (p < 0.01). To further adjust for time of infection, we
used Cox regression analysis with platelet count as time-
dependent variable. Platelets were categorized into groups of
20 × 109/L, and the last platelet count before time of infection
was used for analysis as was described in the BMaterials and
methods^ section. A hazard ration of 0.52 was found meaning
an increase in platelet count of 20 × 109/L leads to a significant
reduction of 52% in chance of infection in the next week (HR
0.52, 95% CI 0.35–0.77, p = 0.001) (Table 2). Adding leuco-
cyte count at t = 0, which was significant (Table 1), to the
model platelet count remained a significant risk factor for
infection (Table 2).
Platelet transfusion in ITP patients
with and without infection
Ninety-one patients (58%) received one or more platelet trans-
fusions during the first month of treatment, where 85% of the
units were transfused within the first week (mean 4.6 ±
4.2 days after inclusion) (Table 1). At t = 0, there is a signifi-
cant lower platelet count in the patient group who received a
transfusion: 8.5 × 109/L versus 19.9 × 109/L (p < 0.01)
(Fig. 3a). During the first month, there is no effect of platelet
transfusion on platelet count (p > 0.05) (Fig. 3a). In the pa-
tients without infection, there is a positive, but not significant,
trend of platelet transfusion on platelet count (Fig. 3b). In the
patients with infection, there seems no effect of platelet trans-
fusion on platelet count (Fig. 3c).
Discussion
The results of this large cohort reveals that an incidence of
24% in the first month of treatment infection is a common
problem in patients with primary ITP. Additionally, patients
with infection had a significant lower response rate at 1 month
compared to patients without infection, possibly contributing
to the significant longer hospital stay. Also, we could show
that platelet count is correlated with infections and additional-
ly that a low platelet count is an independent risk factor for
infection within the next week with a hazard ration of 0.52.
The role of platelet transfusion however remains unclear.
In the last years, more and more research has shown that
platelets can modulate the innate and adaptive immune re-
sponse. Especially for patients with sepsis, it is shown that
thrombocytopenia is a surrogate marker for poor prognosis
[6]. For patients with influenza infection, we could recently
show that higher viral load leads to lower platelet counts and
treatment with a sialidase inhibitor oseltamivir leads to higher
platelet counts [12]. In the current study, we could show that
infection is associated with lower response rates and longer
hospital stay in patients with primary ITP. This might be due
to the immunomodulatory treatment (e.g., steroids) patients
received, although the average time of infection was 5.7 days
after start of steroid therapy, making the role of treatment
smaller in our study. Also, no difference in infection rate for
dexamethasone or prednisone treatment was found. However,
platelets can limit bacterial growth, influence leucocyte re-
cruitment and functions, influence cytokine response, and
Fig. 2 Infection leads to lower response rates at 1 month. Response
according to Rodeghiero et al. (No response: platelet count < 30 × 109/
L; response: platelet count > 30 × 109/L and < 100 × 109/L); complete
response: platelet count > 100 × 109/L [2]. p < 0.05
Table 2 Platelet count is a risk factor for infection
Hazard ratio Standard error 95% CI P value
Platelet count 0.52 0.10 0.35–0.77 0.001
Platelet count
Leucocyte count
0.54
1.10
0.11
0.04
0.37–0.79
1.01–1.19
0.002
0.021
Last platelet count before occurrence of infection was used. Platelets were
grouped into groups per 20 × 109 /L. Cox regression analysis with platelet
count as time-dependent variable was used. Secondary analysis was per-
formed adding leucocyte count to the model
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influence activation of the vascular endothelium and coagula-
tion system [8, 13–22]. Although the mechanism of these
interactions is not fully understood, the expression of func-
tional CD154 (CD40L) is a main contributor [23].
Interestingly, we could show that thrombocytopenia itself
may be an independent and significant risk factor for infec-
tion, strengthening the role of platelets in infections.
Treatment of infections include antibiotic, antiviral, or anti-
fungal therapies. To prevent infection-associated morbidity and
mortality increase in platelet count, e.g., by prophylactic
platelet, transfusions might be the next step. In animal models,
reinfusion of platelets to 10–15% of normal platelet count did
prevent lung and brain bleeding during sepsis. As in theory,
platelet transfusions can be given to prevent infections; during
active infection, post-transfusion increments appear lower and
more platelet transfusions are needed to maintainminimal num-
bers [24]. The beneficial effects of prophylactic platelet trans-
fusion is uncertain and might be influenced by the state of the
infection-induced response system [25]. Specifically in patients
with ITP, prophylactic platelet transfusion is unclear and there-
fore however is not recommended, where in emergency cases,
platelet transfusions can be given in combination with intrave-
nous immunoglobulins (IVIg) [4, 26]. Our study is the first
study providing data on platelet transfusion in ITP patients with
and without infections. However, the primary indication for
platelet transfusion remains still severe bleeding (risk) and pro-
phylactic transfusion is therefore not recommended.
Acute bacterial or viral infections are known to cause ITP
[5, 27]. First-line treatment of patients with ITP is steroids [2].
Next treatment options include for example splenectomy,
TPO agonist, rituximab, and others. Treatment response is
based on increase in platelet count to decrease risk of bleeding
complications. However, according to our study, an increase
in platelet count also leads to a reduction in infection. As
mentioned before, platelet transfusion in patients with primary
ITP is not recommended however, due to the low increments
and risks of transfusion [2].
Limitations of our study are the retrospective nature of
collection of data on infection as this was not the purpose of
the randomized clinical trial. Secondly, infection was mea-
sured as CTC grade 2, thus with clinical symptoms. As we
do not know the exact moment of inoculation, we could only
use the time of clinical manifestation as outcome.
Theoretically, as the thrombocytopenia occurs after the inoc-
ulation of the infection and the thrombocytopenia before the
clinical presentation, thrombocytopenia could still be ex-
plained by the infection itself rather than being a risk factor.
However, with the weekly intervals of platelet count measure-
ments and the average inoculation time of the viral and bac-
terial infections, the relationship between low platelet count
and risk of infections seems true. Additionally, there were no
patients who had high platelet counts before time of infection.
This weakens our Cox regression model with platelet count as
time-dependent variable. Also, it is possible that the thrombo-
cytopenia of some patients, thus the diagnosis ITP, might be a
precursor sign of a hematological malignancy which have an
increased risk of infections. Finally, due to the nature of our
study design, we could only show a correlation and not an
association between platelet count and infections. Further re-
search is needed to confirm a possible association.
In conclusion, an incidence of 24% infection is a common
complication in patient with primary immune thrombocytopenia
leading to a worse response rate at 1 month and a longer hospital
Fig. 3 a Platelet transfusion does not increase platelet count in patients
with ITP. Median platelet counts are shown per patient group. Platelet
count at t = 0 was significantly lower in patients who received platelet
transfusion (p < 0.01). No significant differences were seen at 1, 2, 3, and
4 weeks. b Platelet transfusion increases platelet count in primary ITP
patients without infection. Platelet transfusion leads to higher platelet
counts from day 7 in patients with primary ITP without infection.
Median platelet counts are shown for both groups. No significant
differences were found. c Platelet transfusion does not increase platelet
count in primary ITP patients with infection. In patients with primary ITP
with infection, there is no effect of platelet transfusion on platelet count.
Median platelet counts are shown for both groups. No significant
differences were found
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stay. Low platelet count is correlated with increased risk of in-
fections, strengthening the role of platelets in inflammation, but
the role of platelet transfusion as therapeutic tool remains un-
clear. Further research is needed to investigate the exact mecha-
nism of platelets in the inflammation process and the opportunity
as therapeutic tool.
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